Avaliação econômica dos medicamentos destinados ao tratamento daosteoporose no programa de medicamentos excepcionais do Ministérioda Saúde

Detalhes bibliográficos
Ano de defesa: 2008
Autor(a) principal: Cristina Mariano Ruas Brandao
Orientador(a): Não Informado pela instituição
Banca de defesa: Não Informado pela instituição
Tipo de documento: Dissertação
Tipo de acesso: Acesso aberto
Idioma: por
Instituição de defesa: Universidade Federal de Minas Gerais
UFMG
Programa de Pós-Graduação: Não Informado pela instituição
Departamento: Não Informado pela instituição
País: Não Informado pela instituição
Palavras-chave em Português:
Link de acesso: http://hdl.handle.net/1843/ECJS-7FYMVE
Resumo: The osteoporosis is a typical illness of the elderly and is becoming one of the more frequents and relevants problems of public health. Some medicines are available for the treatment of the osteoporosis and some of them have been dispensed by the Brazilian National Health System(SUS). The objective of this dissertation is to present a systematic review of medicines employed in the treatment of the osteoporosis and an economic evaluation aimed to assess the adequacy of the clinical protocols on the basis of existing scientific evidences in literature.For that, two articles will be presented, the first one, comprise an evaluation of the efficacy, in which was carried out a search of randomized clinical trial in the databases PubMed and LILACS. The studied outcomes had been Bone Mineral Density, incidence of vertebralfractures and adverse reactions. As it intends to carry through a pharmacoeconomic analysis, under perspective of the SUS, with the objective to supply subsidies in the discussion on medicines destined to the treatment of osteoporosis of the Exceptional Drugs Program of theBrazilian Ministry of Health. This article deals with the medicine commercialization in Brazil, focusing on the manufacturers and the patents; on the prices of medicines acquired in the public sector and the national and international market; on the financing of exceptional drugs;on the socio-demographic and clinical profile of the patients who had received exceptional drugs destined to the treatment from osteoporosis in the Minas Gerais Secretary State for Health; and on the characteristics related to the monthly average individual expense with exceptional drugs destined to the treatment of osteoporosis.